SynthesisJournal of gynecologic oncology2026
Pediatric non-gestational choriocarcinoma: systematic literature review and a multicenter case series.
Synthesis in Journal of gynecologic oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Commented on by
Authors and funding
14 authors.
Funding
Abstract
objectiveThis study aimed to explore the key factors affecting the prognosis of pediatric non-gestational choriocarcinoma (PNGC), providing evidence for optimizing clinical treatment and prognosis evaluation.
methodsA systematic literature review was conducted based on online searches of PubMed, Science Direct, and Google Scholar. A retrospective analysis of multi-center pediatric PNGC patients was performed for the period from 2014 to 2024.
resultsAll four patients in our series achieved complete remission and long - term survival following comprehensive treatment. A total of 19 studies involving 70 patients met the inclusion and exclusion criteria for the Systematic search of the literature. Among the 74 patients in this study, 40 received comprehensive treatment. The 3-year overall survival (OS) rate was 50.8%. Univariate survival analysis indicated that age, primary tumor location, and treatment modality influenced OS. However, multivariate analysis revealed that only single - modality treatment or no treatment was associated with an unfavorable prognosis.
conclusionPNGC is a rare and aggressive disease associated with therapeutic challenges and a poor long-term prognosis. The prognosis analysis reveals that the comprehensive treatment plays a crucial role in improving the therapeutic outcome.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.